Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL)

Anthony V. Moorman, PhD, Amir Enshaei, PhD, David O'Connor, MD PhD, Jack Bartram, MD, Jeremy Hancock, PhD, Christine Harrison, Sujith Samarasinghe, MD PhD, John Moppett, MD PhD, Ajay J. Vora, Nicholas Goulden, MD PhD

Blood (2016) 128 (22): 603.

https://doi.org/10.1182/blood.V128.22.603.603

Published: 2016

Journal Articles

Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial

David O'Connor, MD PhD, Jack Bartram, MD, Amir Enshaei, PhD, Anthony V Moorman, PhD, Christine Harrison, PhDFRCPath FMedSci, Rachel Wade, MSc, Rachel Clack, MSc, Jeremy Hancock, PhD, Sujith Samarasinghe, MD PhD, John Moppett, MD PhD, Ajay J. Vora, Nicholas Goulden, MD PhD

Blood (2015) 126 (23): 1412.

https://doi.org/10.1182/blood.V126.23.1412.1412

Published: 2015

Journal Articles

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Blood (2015) 126 (23): 1414.

https://doi.org/10.1182/blood.V126.23.1414.1414

Published: 2015

Journal Articles

Use of Morphological Early Response Data to Predict Relapse in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)

Caroline L Furness, MD, Clare Rowntree, Ajay J. Vora, Amy A Kirkwood, Christopher Mitchell, MBBS, PhD FRCP, Nicholas Goulden, MD PhD, Anthony V. Moorman, PhD, Rachael Hough, MDBMBS,FRCP,FRCPath

Blood (2015) 126 (23): 1415.

https://doi.org/10.1182/blood.V126.23.1415.1415

Published: 2015

Journal Articles

Targeted Inactivation of the c-Myb Oncogene through Integrated Network Analysis

Jasper de Boer, PhD, Vanessa Walf-Vorderwuelbecke, PhD, Gareth Williams, PhD, Sujith Samarasinghe, MD PhD, Phil Ancliff, MD, Nicholas Goulden, MD PhD, Owen Williams, PhD

Blood (2015) 126 (23): 2561.

https://doi.org/10.1182/blood.V126.23.2561.2561

Published: 2015

Journal Articles

Drug Induced MLL Fusion Degradation Via Hsp90 Inhibition

Sandra Cantilena, MPhil, Nicholas Goulden, MD PhD, Owen Williams, PhD, Jasper de Boer, PhD

Blood (2015) 126 (23): 4850.

https://doi.org/10.1182/blood.V126.23.4850.4850

Published: 2015

Journal Articles

The Best of Both? Megadose Stem Cells with CD34 Selection and T-Cell Addback Enables Engraftment from Mismatched Unrelated Donors Using Reduced Toxicity Conditioning in Primary Immunodeficiency

Juliana Montibeller Silva, MD, Kanchan Rao, MNAMS (Paed), MRCP (Paed), Robert Chiesa, Stuart Adams, PhD, Margaret Brocklesby, Gulrukh Ahsan, Giovanna Lucchini, Paul Veys, Persis Jal Amrolia, Nicholas Goulden, MD PhD

Blood (2015) 126 (23): 4303.

https://doi.org/10.1182/blood.V126.23.4303.4303

Published: 2015

Journal Articles

Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD:Â Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003

Jack Bartram, MD, David O'Connor, MD PhD, Amir Enshaei, PhD, Anthony V Moorman, PhD, Christine Harrison, PhDFRCPath FMedSci, Rachel Wade, MSc, Rachel Clack, MSc, Jeremy Hancock, PhD, Sujith Samarasinghe, MD PhD, John Moppett, MD PhD, Ajay J. Vora, Nicholas Goulden, MD PhD

Blood (2015) 126 (23): 806.

https://doi.org/10.1182/blood.V126.23.806.806

Published: 2015

Journal Articles

Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy

Amir Enshaei, PhD, Claire Schwab, Lucy Chilton, PhD, Rachel Wade, MSc, Jeremy Hancock, PhD, Christopher Mitchell, MBBS, PhD FRCP, Sally E Kinsey, Nicholas Goulden, MD PhD, Ajay J. Vora, Christine Harrison, PhDFRCPath FMedSci, Anthony V. Moorman, PhD

Blood (2015) 126 (23): 805.

https://doi.org/10.1182/blood.V126.23.805.805

Published: 2015

Journal Articles

Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003

Rob S Sellar, MBChB, FRCPath, Clare Rowntree, PhD, Ajay J. Vora, Caroline L Furness, MD, Nicholas Goulden, MD PhD, Chris Mitchell, FRCPCH, Anthony V. Moorman, PhD, Rachael Hough, MDBMBS,FRCP,FRCPath

Blood (2015) 126 (23): 2493.

https://doi.org/10.1182/blood.V126.23.2493.2493

Published: 2015

Journal Articles

Analysis of Long-Term Outcomes, Management and Prevalence of Osteonecrosis in UKALL 2003: 3.5% of Adolescents and Young Adults over 10 Years of Age with Acute Lymphoblastic Leukaemia Required Hip Replacement

Nadia L Amin, MBChB, MSc, MA, Sally Kinsey, MD FRCP, FRCPath, Richard Feltbower, PhD MSc, BSc, Ajay J. Vora, Nicholas Goulden, MD PhD, Rachel Wade, MSc, Chris Mitchell, FRCPCH, Rachael Hough, MDBMBS,FRCP,FRCPath, Clare Rowntree, PhD, Beki James, PhD MBChB, MA

Blood (2015) 126 (23): 2083.

https://doi.org/10.1182/blood.V126.23.2083.2083

Published: 2015

Journal Articles

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

Waseem Qasim, MBBS PhD, Persis Jal Amrolia, Sujith Samarasinghe, MD PhD, Sara Ghorashian, MD PhD FRCPath, Hong Zhan, PhD, Sian Stafford, PhD, Katie Butler, PhD, Gul Ahsan, Kimberly Gilmour, Stuart Adams, PhD, Danielle Pinner, Robert Chiesa, Steve Chatters, PhD, Sue Swift, PhD, Nicholas Goulden, MD PhD, Karl Peggs, MBBChir, MRCP, FRCPath, Adrian J Thrasher, MD PhD, Paul Veys, Martin Pule, PhD

Blood (2015) 126 (23): 2046.

https://doi.org/10.1182/blood.V126.23.2046.2046

Published: 2015

Journal Articles

EBF1-PDGFRΒ Fusion in Paediatric Acute Lymphoblastic Leukaemia (ALL): Genetic Profile and Clinical Implications

Claire Schwab, Rebecca Andrews, Lucy Chilton, Alannah Elliott, Gerald Keil, Stacey Richardson, Sarra L. Ryan, Christopher Wragg, John Moppett, Michelle Cummins, MD, Nicholas Goulden, MD PhD, Ajay J. Vora, Anthony V. Moorman, Christine J. Harrison

Blood (2014) 124 (21): 1068.

https://doi.org/10.1182/blood.V124.21.1068.1068

Published: 2014

Journal Articles

No Evidence That PTEN Abnormalities Impact on Outcome in Pediatric Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated on the MRC UKALL2003 Trial

Sarah Jenkinson, MSc, Amy A Kirkwood, Nicholas Goulden, MD PhD, Ajay J. Vora, Chris Mitchell, Rachel Wade, Jeremy Hancock, Anthony V. Moorman, PhD, David C Linch, FMedSci, Rosemary E Gale

Blood (2014) 124 (21): 1077.

https://doi.org/10.1182/blood.V124.21.1077.1077

Published: 2014

Journal Articles

SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome

Claire Schwab, Rebecca Andrews, Lucy Chilton, Alannah Elliott, Stacey Richardson, Sarra L. Ryan, Amy Logan, Adele K. Fielding, Nicholas Goulden, MD PhD, Ajay J. Vora, Anthony V. Moorman, Christine A. Macartney, Christine J. Harrison

Blood (2014) 124 (21): 3773.

https://doi.org/10.1182/blood.V124.21.3773.3773

Published: 2014

Journal Articles

Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study

Martin Pule, Sara Ghorashian, MD PhD FRCPath, Laura Clifton-Hadley, PhDBSc, Paul Smith, Soraya Saiagh, Paul Veys, FRCP,FRCPath, Nicholas Goulden, MD PhD, Gary Wright, Ettore Biagi, MD PhD, Bianca Altvater, PhD, Brigitte Dreno, MD, Kim Champion, PhD, Michelle Cummins, MD, Rachael Hough, MDBMBS,FRCP,FRCPath, Martin G. Sauer, MD, Claudia Rossig, MD, Persis Amrolia

Blood (2014) 124 (21): 383.

https://doi.org/10.1182/blood.V124.21.383.383

Published: 2014

Journal Articles

Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial

Katharine Patrick, Rachel Wade, Nicholas Goulden, MD PhD, Chris Mitchell, Clare Rowntree, FRCPath, Jeremy Hancock, Rachael E Hough, MD, Ajay J. Vora, FRCPath

Blood (2014) 124 (21): 3702.

https://doi.org/10.1182/blood.V124.21.3702.3702

Published: 2014

NARROW

Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL)

Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Use of Morphological Early Response Data to Predict Relapse in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)

Targeted Inactivation of the c-Myb Oncogene through Integrated Network Analysis

Drug Induced MLL Fusion Degradation Via Hsp90 Inhibition

The Best of Both? Megadose Stem Cells with CD34 Selection and T-Cell Addback Enables Engraftment from Mismatched Unrelated Donors Using Reduced Toxicity Conditioning in Primary Immunodeficiency

Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD:Â Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003

Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy

Relapse in Teenage and Young Adult (TYA) Patients Treated on a Pediatric Minimal Residual Disease (MRD) Stratified Protocol Is Associated with a Poor Outcome: Results from UKALL2003

Analysis of Long-Term Outcomes, Management and Prevalence of Osteonecrosis in UKALL 2003: 3.5% of Adolescents and Young Adults over 10 Years of Age with Acute Lymphoblastic Leukaemia Required Hip Replacement

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

EBF1-PDGFRΒ Fusion in Paediatric Acute Lymphoblastic Leukaemia (ALL): Genetic Profile and Clinical Implications

No Evidence That PTEN Abnormalities Impact on Outcome in Pediatric Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated on the MRC UKALL2003 Trial

SSBP2-CSF1R Is a Recurrent Fusion in B-Other Acute Lymphoblastic Leukaemia with Variable Clinical Outcome

Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study

Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only